跳至主要内容
临床试验/NCT06156774
NCT06156774招募中不适用

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Fondazione Italiana Linfomi - ETS21 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2024年4月18日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
130
试验地点
21
主要终点
Best Overall Response Rates (ORR)

研究概览

简要总结

This is a multicenter prospective observational study lead by the FIL on sarcopenia and sGA as possible predictors of efficacy and toxicity outcomes in patients undergoing CAR-T cells treatment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients (≥ 18 years old).
  • Patients with B-cell non-Hodgkin Lymphoma scheduled to received CAR-T cell product according to Agenzia Italiana del Farmaco (AIFA) indications and technical data sheet of the drug
  • Availability of a 18F-FDG PET/CT scan or a full dose CT scan (without contrast media) pre-treatment with CART
  • Written informed consent voluntarily provided

排除标准

  • Patients not fulfilling the eligibility criteria

结局指标

主要结局

Best Overall Response Rates (ORR)

时间窗: up to 28 months

Best Overall Response Rates (ORR) after CAR-T therapy according to the presence or absence of sarcopenic status

次要结局

  • Overall Survival (OS)(up to 28 months)
  • Progression-Free Survival (PFS)(up to 28 months)
  • Best Complete Remission Rates (CRR)(up to 28 months)
  • Incidence of CAR-T related toxicities(up to 28 months)
  • Rate of admission to Intensive Care Units (ICU)(up to 28 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (21)

Loading locations...

相似试验